Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Design Therapeutics Inc.

    NASDAQ: DSGN · Real-Time Price · USD
    3.57
    -0.25 (-6.54%)
    At close: Jun 27, 2025, 3:59 PM
    3.57
    0.00%
    After-hours: Jun 27, 2025, 04:34 PM EDT

    Design Therapeutics Statistics

    Share Statistics

    Design Therapeutics has 56.77M shares outstanding. The number of shares has increased by 0.47% in one year.

    Shares Outstanding

    n/a
    		 56.77M

    Shares Change (YoY)

    n/a
    		 0.47%

    Shares Change (QoQ)

    n/a
    		 0.25%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 30.87M

    Failed to Deliver (FTD) Shares

    n/a
    		 69

    FTD / Avg. Volume

    n/a
    		 0.06%

    Short Selling Information

    The latest short interest is 3.66M, so 6.44% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 3.66M

    Short % of Shares Out

    n/a
    		 6.44%

    Short % of Float

    n/a
    		 9.76%

    Short Ratio (days to cover)

    n/a
    		 39.84

    Valuation Ratios

    The PE ratio is -7.04 and the forward PE ratio is -3.24. Design Therapeutics's PEG ratio is 0.27.

    PE Ratio

    n/a
    		 -7.04

    Forward PE

    n/a
    		 -3.24

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 4

    PB Ratio

    n/a
    		 1.44

    P/FCF Ratio

    n/a
    		 -8.04

    PEG Ratio

    n/a
    		 0.27
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Design Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 29.31, with a Debt / Equity ratio of 0.01.

    Current Ratio

    n/a
    		 29.31

    Quick Ratio

    n/a
    		 29.31

    Debt / Equity

    n/a
    		 0.01

    Debt / EBITDA

    n/a
    		 -0.05

    Debt / FCF

    n/a
    		 -0.05

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-885,500

    Employee Count

    n/a
    		 56

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 14.33% in the last 52 weeks. The beta is 1.62, so Design Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.62

    52-Week Price Change

    n/a
    		 14.33%

    50-Day Moving Average

    n/a
    		 3.86

    200-Day Moving Average

    n/a
    		 4.85

    Relative Strength Index (RSI)

    n/a
    		 48.41

    Average Volume (20 Days)

    n/a
    		 114,062

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -62.38M

    Net Income

    n/a
    		 -49.59M

    EBITDA

    n/a
    		 -48.99M

    EBIT

    n/a
    		 -49.59M

    Earnings Per Share (EPS)

    n/a
    		 -0.88
    Full Income Statement

    Balance Sheet

    The company has 22.56M in cash and 2.33M in debt, giving a net cash position of 20.23M.

    Cash & Cash Equivalents

    n/a
    		 22.56M

    Total Debt

    n/a
    		 2.33M

    Net Cash

    n/a
    		 20.23M

    Retained Earnings

    n/a
    		 -227.21M

    Total Assets

    n/a
    		 237.47M

    Working Capital

    n/a
    		 225.41M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -43.1M and capital expenditures -340K, giving a free cash flow of -43.45M.

    Operating Cash Flow

    n/a
    		 -43.1M

    Capital Expenditures

    n/a
    		 -340K

    Free Cash Flow

    n/a
    		 -43.45M

    FCF Per Share

    n/a
    		 -0.77
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    DSGN does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for DSGN is $4, which is 4.4% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $4

    Price Target Difference

    n/a
    		 4.4%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 1
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 13

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist